Raul J. Cano, at California Polytechnichal State University, just spoke to a packed room about ongoing developments in treating antibiotic resistant superbugs--particularly MRSA. Laboratorians are acutely aware of the importance of accurate testing for MRSA in order to allow physicians to quickly treat and isolate infected patients. Luckily, some newer microbials show promise for treating this challenging infection: Linezolid, Daptomycin, Tigecycline, Retspamulin, Telavancin, Dalbavancin, Iclaprim and Rifamycin.
Cano notes that while these are promising for the treatment of MRSA, resistance is continually evolving, and everyone in the healthcare field must remain cognizant.